-
2 weeks ago | 
healio.com | Raj Chovatiya |Erin Michael
Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of Dermatology Annual Meeting. The study assessed the use of the interleukin-23 inhibitor icotrokinra (Protagonist Therapeutics, Johnson & Johnson) in adult and adolescent patients with moderate-to-severe plaque psoriasis.
-
4 weeks ago | 
healio.com | Raj Chovatiya |Erin Michael
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting. The study assessed the use of ESK-001 (Alumis), an oral tyrosine kinase 2 inhibitor, among patients with moderate-to-severe plaque psoriasis.
-
4 weeks ago | 
healio.com | Raj Chovatiya |Erin Michael |Carol L. DiBerardino
In this video, Raj Chovatiya, MD, PhD, discusses updates on oral therapies in psoriasis from the American Academy of Dermatology Annual Meeting. “We saw updates largely in the oral therapeutic realm, even more so than the biologic therapeutic realm,” Chovatiya, who is a clinical associate professor for Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, said.
-
2 months ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this exclusive video, Lawrence F. Eichenfield, MD, a member of the Healio Dermatology Peer Perspective Board, discusses psoriasis case reports presented at Maui Derm 2025.
-
2 months ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, discusses areas of unmet need in the field of psoriasis.
-
2 months ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, discusses oral treatments available to pediatric and adolescent psoriasis discussed at Maui Derm 2025. “From a systemic agent standpoint, we’ve never had an oral agent approved for psoriasis,” Eichenfield, who is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and vice chair of the department of dermatology at University of California, San Diego, told Healio.
-
2 months ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, talks about takeaways in updates on topical treatments for pediatric and adolescent psoriasis discussed at Maui Derm 2025.
-
Jan 15, 2025 | 
healio.com | Paolo Caimi MD |Erin Michael |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual Meeting and Exposition.
-
Jan 15, 2025 | 
healio.com | Paolo Caimi MD |Erin Michael |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — Healio spoke with Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, about results from the inMind trial presented at ASH Annual Meeting and Exposition.
-
Jan 14, 2025 | 
healio.com | Paolo Caimi MD |Erin Michael |Mindy Valcarcel
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — Paolo Caimi, MD, spoke with Healio about the latest results from the POLARIX trial presented at ASH Annual Meeting and Exposition.
